Contact Information

thomas.beimers@FaegreBD.com2200 Wells Fargo Center
90 S. Seventh Street

Minneapolis, Minnesota 55402

T: +1 612 766 8856
F: +1 612 766 1600


University of Minnesota Law School
J.D., magna cum laude, Minnesota Law Review (articles editor) (1998)
Macalester College
B.A. in Political Science (1991)

Bar Admissions

District of Columbia Minnesota

Court Admissions

U.S. Court of Appeals for the District of Columbia Circuit U.S. Court of Appeals for the Eighth Circuit U.S. Court of Appeals for the Fifth Circuit U.S. Court of Appeals for the Fourth Circuit U.S. Court of Appeals for the Ninth Circuit U.S. Supreme Court

Thomas W. Beimers


Thomas Beimers counsels health care clients on regulatory, compliance and health care fraud matters. Before joining Faegre Baker Daniels, Thomas was senior counsel for Administrative and Civil Remedies in the Department of Health and Human Services' Office of the Inspector General, where he investigated and litigated health care fraud matters from 2007 to 2011. He settled False Claims Act cases involving off-label marketing, drug pricing, kickback violations, and Medicaid and Medicare reimbursement rules. From 2008 to 2010, he served as special assistant United States attorney, prosecuting criminal health care fraud cases as part of the Justice Department's Medicare Fraud Strike Force.

As counsel to the Inspector General's office, Thomas also brought cases under the Civil Monetary Penalties Law and the Exclusion Statute.  He has expertise in matters involving the False Claims Act; Anti-Kickback Statute; Stark Law; federal Food, Drug and Cosmetic Act; HIPAA; the Controlled Substances Act; and regulations governing the pricing and promotion of pharmaceuticals and medical devices.

Thomas assists clients in responding to health care fraud investigations and represents them in criminal, civil and administrative proceedings, including by conducting internal investigations and providing risk management services. He has experience negotiating and monitoring corporate integrity agreements involving major pharmaceutical and medical device manufacturers and developing compliance programs and risk management plans for both manufacturers and health care providers, including hospital systems, physician practices, and pharmacies.

Thomas began his career as an associate in the health care regulatory, government enforcement and appellate groups of two Washington, D.C. law firms.


  • HHS Inspector General's Exceptional Achievement Award, 2010-11
  • Department of Justice Assistant Attorney General's Award, 2010
  • FBI Commendation in recognition of exceptional prosecutorial skills, 2010
  • Minnesota Law Review — Outstanding Student Comment, 1998
  • Robert A. Stein Scholar, 1995-98

Professional Associations

  • American Health Lawyers Association
  • Health Care Compliance Association
  • Federal Bar Association
  • American Bar Association
  • Warren E. Burger Inn of Court

Civic Activities

  • Jungle Theater, Minneapolis — Board of Directors
  • Harvard World Teach Program — Former Volunteer English Teacher


  • Eighth Circuit Court of Appeals, Hon. Gerald W. Heaney, 1998-99


  • Investigations for Life Sciences Companies: What to Do When the Government Knocks
    Co-presenter, Expert Insights on Fraud & Abuse, Government Investigations & Regulated Research in Health Care & Life Sciences, Indianapolis Bar Association CLE Update, February 20, 2014
  • The Best Defense: Revamping Compliance Programs Based on Takeaways From Recent Corporate Integrity Agreements
    Fraud and Abuse in the Sales and Marketing of Drugs Conference, New York, March 2013
  • The Sunshine Act Final Rule
    LifeScience Alley, Minneapolis, March 2013
  • Agency Expectations for Compliance Programs
    13th Annual Pharmaceutical Regulatory and Compliance Congress, Washington, D.C., November 2012
  • How New Corporate Integrity Agreements Impact Physician Practices
    Health Care Compliance Association Clinical Practice Compliance Conference, Philadelphia, October 2012
  • New Standards: What Enhanced Corporate Integrity Obligations Tell Us About OIG Expectations for Compliance Programs
    AHLA/HCCA Fraud and Compliance Forum, Baltimore, September 2012
  • What Is the OIG Telling Us About Current Expectations for Compliance Programs?
    Health Care Compliance Association Compliance Institute, Las Vegas, May 2012
  • Addressed Healthcare Distribution Management Association on Importance of Timely Average Manufacturer's Price Reporting
    Washington D.C., November 2010
  • Presentation and Panel Lead on Various Aspects of Freedom of Information Law as an IREX ProMedia-Sponsored Expert
    Gorno Vranovci, Macedonia, June 2000
  • Presentation and Panel Lead on Various Aspects of Freedom of Information Law as an IREX ProMedia-Sponsored Expert
    Pristina, Kosovo, May 2002

Published Articles

  • Is Off-Label Enforcement Off Limits?
    Beyond Healthcare Reform, December 7, 2012
  • The RAC Wars – The Latest Shot
    Beyond Healthcare Reform, November 21, 2012
  • With Boehringer Ingelheim FCA Settlement, Government Continues to Expand Off-Label Enforcement and Expand CIAs
    Beyond Healthcare Reform, October 31, 2012
  • Caught By the CIA: Corporate Integrity Agreement Is Grounds for FCA Liability
    AHLA Fraud & Abuse Newsletter, June 2012
  • The Departmental Appeals Board (Re)Defines the "Should Have Known" Standard for Exclusion Actions Under 1128(b)(7)
    Beyond Healthcare Reform, April 19, 2012
  • OIG Reports on Pharma Compliance Roundtable
    Beyond Healthcare Reform, March 28, 2012
  • District Court Decisions Help Refine Heightened Pleading Standard for False Claims Act Cases
    Beyond Healthcare Reform, March 15, 2012
  • Where Is The Corporate Integrity Agreement?
    Law360, February 27, 2012
  • Searching For The Structural Vision of City of Boerne v. Flores:  Vertical and Horizontal Tensions In The New Constitutional Architecture
    26 Hastings Const. L.Q. 789, 1999


Transmission of information to us via this feature does not establish an attorney-client relationship. Do not send any information that you would have treated confidentially.